(Q45149956)

10 December 2017

Phase I study comparing continuous infusion of recombinant interleukin-2 by subcutaneous or intravenous administration (English)

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90453-9

17 October 2022

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90453-9

17 October 2022

1

M. G. Leahy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627372

17 October 2022

author name string

D. Pitfield

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627372

17 October 2022

S. Popert

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627372

17 October 2022

C. J. Gallagher

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627372

17 October 2022

R. T. Oliver

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627372

17 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1627372

17 October 2022

publication date

1 January 1992

1 reference

full work available at URL

10 December 2017

https://api.elsevier.com/content/article/PII:0959804992904539?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90453-9

https://api.elsevier.com/content/article/PII:0959804992904539?httpAccept=text/plain

17 October 2022

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90453-9

European Journal of Cancer

17 October 2022

published in

1 reference

10 December 2017

28A

1 reference

10 December 2017

6-7

1 reference

10 December 2017

1049-1051

1 reference

New views on rejection mechanisms and their relevance to interleukin-2 as a treatment for renal cell cancer

10 December 2017

1

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90453-9

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

17 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90453-9

Evaluation of the effect of continuous infusion recombinant interleukin-2 (bioleukin) on peripheral blood leucocytes of patients with terminal malignancy

17 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90453-9

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

17 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90453-9

Prognostic factors in metastatic renal carcinoma

17 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90453-9

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

17 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90453-9

Low-dose regimen of interleukin-2 for metastatic renal carcinoma.

17 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90453-9

The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]

17 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90453-9

17 October 2022

Identifiers

1 reference

10 December 2017

1 reference